Ultrastructural evaluation of the effect of N-acetylcysteine on methotrexate nephrotoxicity in rats

Histology and Histopathology

Volumn 28, Issue 7, 2013, Pages 865-874

  Çaǧlar, Yidiz ^a   Özgür, Hülya ^a   Matur, Irem ^a   Yenilmez, Ebru Dündar ^a   Tuli, Abdullah ^a   Gönlüşen, Gülfiliz ^a   Polat, Sait ^a  

^a CUKUROVA UNIVERSITY   (Turkey)

Author keywords

Kidney; Methotrexate; N Acetylcysteine; Toxicity; Ultrastructure

Indexed keywords

ACETYLCYSTEINE; CREATININE; GLUTATHIONE PEROXIDASE; KI 67 ANTIGEN; MALONALDEHYDE; METHOTREXATE; SUPEROXIDE DISMUTASE;

ANIMAL; ARTICLE; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; GLOMERULUS; IMMUNOHISTOCHEMISTRY; KIDNEY; KIDNEY FAILURE; MALE; METABOLISM; RAT; ULTRASTRUCTURE; UREA NITROGEN BLOOD LEVEL; WISTAR RAT;

ACETYLCYSTEINE; ANIMALS; BLOOD UREA NITROGEN; CREATININE; GLUTATHIONE PEROXIDASE; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; KIDNEY; KIDNEY GLOMERULUS; MALE; MALONDIALDEHYDE; METHOTREXATE; RATS; RATS, WISTAR; RENAL INSUFFICIENCY; SUPEROXIDE DISMUTASE;

RATTUS;

EID: 84879750762     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Abraham P., Indirani K. and Sugumar E. (2007). Effect of cyclophosphamide treatment on selected lysosomal enzymes in the kidney of rats. Experimental and Toxicol. Pathol. 59, 143-149.
2. Al-Ali S.Y., Hassan I.M. and Sadek S. (2005). Ultrastructural changes in rat livers perfused in vitro and in vivo with a high dose of methotrexate. Histol. Histopathol. 20, 1131-1145.
3. Atkuri K.R., Mantovani J.J., Herzenberg L.A. and Herzenberg L.A. (2007). N-Acetyl cysteine a safe antidote for cysteine/glutathione deficiency. Pharmacology 7, 355-359.
4. Babiak R.M., Campello A.P., Carnieri E.G. and Oliveira M.B. (1998). Methotrexate: pentose cycle and oxidative stress. Cell Biochem. Funct. 16, 283-293.
5. Behling E.B., Sendão M.C., Francescato H.D., Antunes L.M., Costa R.S. and Bianchi M.L. (2006). Comparative study of multiple dosage of quercetin against cisplatin-induced nephrotoxicity and oxidative stress in rat kidneys. Pharmacol. Rep. 58, 526-532.
6. Behr J., Maier K and Degenkolb B. (1997). Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression. Am. J. Respir. Crit. Care Med. 156, 1897-1901.
7. Benesic A., Schwerdt G., Freudinger R., Mildenberger S., Groezinger F., Wollny B., Kirchhoff A. and Gekle M. (2006). Chloroacetaldehyde as a sulfhydryl reagent: the role of critical thiol groups in ifosfamide nephropathy. Kidney Blood Press Res. 29, 280-293.
8. Beutler E. (1975). Red cell metabolism. 2nd edition. Grune and Stratton. NewYork. 74, 131-132.
9. El-Badawi M.G., Abdalla M.A., Bahakim H.M. and Fadel R.A. (1996). Nephrotoxicity of low-dose MTX in guinea pigs: an ultrastructural study. Nephron 73, 462-466.
10. Fan C., Cool J.C., Scherer M.A., Foster B.K., Shandala T., Tapp H. and Xian C.J. (2009). Damaging effects of chronic low-dose methotrexate usage on primary bone formation in young rats and potential protective effects of folinic acid supplementary treatment. Bone 44, 61-70.
11. Fridovich I. (1974). Superoxide dismutase. Adv. Enzymol. 41, 35-97.
12. Frouin I., Prosperi E., Denegri M., Negri C., Donzelli M., Rossi L., Riva F., Stefanini M. and Scovassi A.I. (2001). Different effects of methotrexate on DNA mismatch repair proficient and deficient cells. Eur. J. Cancer 37, 1173-1180.
13. Fuskevåg O.M., Kristiansen C., Olsen R., Aarbakke J. and Lindal S. (2000). Microvascular perturbations in rats receiving the maximum tolerated dose of methotrexate or its major metabolite 7-hydroxymethotrexate. Ultrastruct. Pathol. 24, 325-332.
14. Gao F., Nakamaru M., Masubuchi Y. and Horie T. (2001). Protective effect of a sythetic analog of prostoglandin E1 on the small intestinal damage induced by the administration of methotrexate to rats. J. Pharm. Sci. 90, 1040-1048.
15. Grönroos M., Chen M., Jahnukainen T., Capitanio A., Aizman RI. and Celsi G. (2006). Methotrexate induces cell swelling and necrosis in renal tubular cells. Pediatr. Blood Cancer 46, 624-629.
16. Hempel L., Misselwitz J., Fleck C., Kentouche K., Leder C., Appenroth D., Rost M. and Zintl F. (2003). Influence of high-dose methotrexate therapy (HD-MTX) on glomerular and tubular kidney function. Med. Pediatr. Oncol. 40, 348-354.
17. Hornung N., Ellingsen T., Attermann J., Stengaard-Pedersen K. and Poulsen J.H. (2008). Patients with rheumatoid arthritis treated with methotrexate (MTX): concentrations of steady-state erythrocyte MTX correlate to plasma concentrations and clinical efficacy. J. Rheumatol. 35, 1709-1715.
18. Hytiroglou P., Tobias H., Saxena R., Abramidou M., Papadimitriou C.S. and Theise N.D. (2004). The canals of hering might represent a target of methotrexate hepatic toxicity. Am. J. Clin. Pathol. 121, 324-329.
19. Jahovic N., Cevik H., Sehirli A.O. and Yegen B.C. (2003). Melatonin prevents methotrexate-induced hepatorenal oxidative injury in rats. J Pineal Res. 3, 282-287.
20. Jansen G., Mauritz R.M., Assaraf Y.G., Sprecher H., Drori S., Kathmann I., Westerhof G.R., Priest D.G., Bunni M., Pinedo H.M., Schornagel J.H. and Peters G.J. (1997). Regulation of carrier-mediated transport of folates and antifolates in methotrexate-sensitive and resistant leukemia cells. Adv. Enzyme Regul. 37, 59-76.
21. Jolivet J., Cowan K.H., Curt G.A., Clendeninn N. and Chabner B.A. (1983). The Pharmacology and clinical use of methotrexate. N. Engl. J. Med. 309, 1094-1104.
22. Kintzel P.E. (2001). Anticancer drug-induced kidney disorder. Drug Safety 2, 19-38.
23. Kolli V.K., Abraham P., Isaac B and Selvakumar D. (2009). Neutrophil infiltration and oxidative stress may play a critical role in methotrexate-induced renal damage. Chemotherapy 55, 83-90.
24. Kuhn A., Ruland V., Patsinakidis N and Luger T.A. (2010). Use of methotrexate in patients with psoriasis. Clin. Exp. Rheumatol. 28, 138-144.
25. Lankelma J., Van der Klein E. and Ramaekers F. (1980). The role of 7-hydroxymethotrexate during methotrexate anti-cancer therapy. Cancer Lett. 9, 133-142.
26. Li T., Ito K., Sumi S.I., Fuwa T. and Horie T. (2009). Protective effect of aged garlic extract on the apoptosis of intestinal epithelial cells caused by methotrexate. Cancer Chemother. Pharmacol. 63, 873-880.
27. Miguel D., García-Suárez J., Martín Y., Gil-Fernández J.J. and Burgaleta C. (2008). Severe acute renal failure following high-dose methotrexate therapy in adults with haematological malignancies: a significant number result from unrecognized co administration of several drugs. Nephrol Dial. Transplant. 23, 3762-3766.
28. Mohamadin A.M., El-Beshbishy H.A. and El-Mahdy M.A. (2005). Green tea extract attenuates cyclosporine A-induced oxidative stress in rats. Pharmacol. Res. 51, 51-57.
29. Naruhashi K., Nadai M., Nakao M., Suzuki N., Nabestima T. and Hasegawa T. (2000). Changes in absorbtive function of rat intestine injured by methotrexate. Clin. Exp. Pharmacol Physiol. 27, 980-986.
30. Ohkawa H., Ohishi N. and Yagi K. (1979). Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 95, 351-358.
31. Purcell W.T. and Ettinger D.S. (2003). Novel antifolate drugs. Curr. Oncol. Rep. 5, 114-125.
32. Ramesh H., Pillai R.K., Abraham T., Padmaje N.P., Hameed S. and Vijayaraghavan G. (2006). Reno-protective effect on NAC in patients with impaired renal function undergoing coronary angiography and interventions. J. Assoc. Physicians. India 54, 449-452.
33. Sansone R. and Sansone L.A. (2011). Getting a knack for NAC: NAcetyl-Cysteine. Innov. Clin. Neurosci. 8, 10-14.
34. Schwartz S., Borner K., Müler K., Martus P., Fischer L., Korfel A., Auton T. and Thiel E. (2007). Glucarpidase (Carboxypeptidase G2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy. Oncologist 12, 1299-1308.
35. Seideman P., Müler-Suur R. and Erkman E. (1993). Renal effect of low dose methotrexate in rheumatoid arthritis. J. Rheumatol. 20, 1126-1128.
36. Shrestha S., Dhungel S., Saxena A.K., Bhattacharya S. and Maskey D. (2007). Effect of methotrexate (MTX) administration on spermatogenesis: an experimental on animal model. Nepal Med. Coll. J. 9, 230-233.
37. Skretkowicz J., Sekulska M., Danilewicz M., Wagrowska-Danilewicz M. and Polakowski P. (1996). Effect of some anticancer drugs and combined chemotherapy on renal toxicity. Biol. Signals 5, 51-58.
38. Smeland E., Fuskevag O.M., Nymann K., Svendesn J.S., Olsen R., Lindal S., Bremnes R.M. and Aarbakke J. (1996). High-dose 7-hydromethotrexate: acute toxicity and lethality in rat model. Cancer Chemother. Pharmacol. 37, 415-422.
39. Tariq M., Morais C., Sobki S., Al Sulaiman M. and Al Khader A. (1999). N-acetylcysteine attenuates cyclosporin-induced nephrotoxicity in rats. Nephrol. Dial. Transplant. 14, 923-929.
40. Tirouvanziam R., Conrad C.K., Bottiglieri T., Herzenberg LA. and Moss R.B. (2006). High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. Proc. Natl. Acad Sci. USA 103, 4628-4633.
41. Uz E., Öktem F., Yi{dotless}lmaz H.R., Uzar E. and Özgüner F. (2005). The activities of purin-catabolizing enzymes and the level of nitric oxide in rat kidneys subjected to MTX:protective effect of caffeic acid phenethyl ester. Mol. Cell. Biochem. 277, 165-170.
42. Vardi N., Parlakpinar H., Ozturk F., Ates B., Gul M., Cetin A., Erdogan A. and Otlu A. (2008). Potent protective effect of apricot and ßcarotene on methotrexate-induced intestinal oxidative damage in rats. Food Chem. Toxicol. 46, 3015-3022.
43. Vezmar S., Becker A., Bode U. and Jaehde U. (2003). Biochemical and clinical aspects of methotrexate neurotoxicity. Chemotherapy 49, 92-104.
44. Weisman M.H., Furst D.E., Park G.S., Kremer J.M., Smith K.M., Wallace D.J., Caldwell J.R. and Dervieux T. (2006). Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis. Arthritis Rheumatism 54, 607-612.
45. Widemann B.C., Balis F.M., Kempf-Bielack B., Bielack S., Pratt C.B., Ferrari S., Bacci G., Craft A.W. and Adamson P.C. (2004). Highdose methotrexate-induced nephrotoxicity in patients with osteosarcoma. Cancer 100, 2222-2232.
46. Widemann B.C. and Adamson P.C. (2006). Understanding and managing methotrexate nephrotoxicity. Oncologist 11, 694-703.
47. Winick N.J., Kamen B.A., Balis F.M., Holcenberg J., Lester C.M. and Poplack D.G. (1987). Folate and methotrexate polyglutamate tissue levels in rhesus monkeys following chronic low-dose methotrexate. Cancer Drug Deliv. 4, 25-31.